A study was conducted to determine the safety and efficacy of topically applied ciprofloxacin ophthalmic solution in a pediatric population experiencing acute bacterial conjunctivitis. Topically applied ciprofloxacin (3 mg/mL) is known to be a safe and effective treatment for adults suffering from bacterial conjunctivitis; however, the safety and effectiveness of this broad-spectrum fluoroquinolone in pediatric patients is not well established. Ciprofloxacin was evaluated in a double-blind, randomized, controlled study of 257 patients ranging from 0 (i.e., less than 1 year) to 12 years of age from 33 geographically diverse medical centers. The children received either 0.3% ciprofloxacin ophthalmic solution (Ciloxan, Alcon Laboratories, Fort Worth, TX) or tobramycin ophthalmic solution (Tobrex, Alcon Laboratories, Fort Worth, TX). Both test medications were administered topically every 2 hours on days 1 and 2 followed by every 4 hours on days 3 through 7. Eyes were cultured prior to enrollment and again on day 7. Treatment efficacy as determined by microbiological culture data and physicians' judgment of overall resolution was similar for the ciprofloxacin and tobramycin groups. Microbiological eradication was observed in 90.1% of the ciprofloxacin group and 84.3% of the tobramycin group (P = 0.29). Physicians judged 87.0% of the ciprofloxacin patients and 89.9% of the tobramycin patients clinically cured on day 7 (P > 0.5). There were no serious adverse medical events attributable to either treatment. This study showed that topically applied ciprofloxacin ophthalmic solution is safe and effective in a pediatric population experiencing acute bacterial conjunctivitis.

Objetivo: Comparar los resultados de los tratamientos homeopático y convencional sobre la epidemia de conjuntivitis viral del año 1997 en Ranchuelo, VC, Cuba. Material y métodos: Se trata de un estudio retrospectivo de un total de 67 pacientes que se diagnosticaron y se ingresaron durante la epidemia de conjuntivitis viral que se produjo en los meses de julio a septiembre de 1997 en el área de salud de Ranchuelo, conformados en dos grupos, un primer grupo de 47 pacientes tratados con medicamentos convencionales y un segundo grupo de 20 pacientes tratados con medicamentos homeopáticos, Resultados: Se comprobó que el tratamiento homeopático produjo la curación en menor tiempo, necesitando el otro tratamiento casi el doble del tiempo y además, que el tratamiento homeopático demostró ser más barato que el convencional, siendo el costo de éste último más del doble. Conclusiones: Quedó demostrada la buena acción del medicamento homeopático sobre la epidemia, con la curación que se produjo en mucho menos tiempo y con menos costo que con los otros medicamentos.

OBJECTIVE:

To discover the best treatments for acute infective conjunctivitis and to discern whether antibiotics are necessary for the resolution of bacterial conjunctivitis in particular.

QUALITY OF EVIDENCE:

MEDLINE, EMBASE, and the Cochrane Database of Systematic reviews were searched. Findings were limited to full-text articles from core clinical journals in the English language, and are based on level I or level II evidence. Clinical Evidence was also searched, from which moderate-quality results have been cited.

MAIN MESSAGE:

Infective conjunctivitis should be managed conservatively, with antibiotics prescribed either after a delayed period if symptoms do not improve within 3 days of onset, or not at all. This approach helps to prevent the medicalization of the condition (reducing consultations for future occurrences) and discourages the unnecessary use of antibiotics, which might delay diagnosis of other serious red eye conditions. Physicians and patients should be educated on the self-limiting nature of the condition to increase compliance with conservative treatment and change the management expectations of parents and schools.

CONCLUSION:

Acute infective conjunctivitis is the most common ocular complaint dealt with in family practice; its viral and bacterial etiologies are difficult to distinguish on clinical grounds alone. Evidence suggests that properly educating patients with written information materials is the most effective way to manage this simple ailment and increase patient satisfaction.

Este artículo no tiene resumen

Chlamydia has been found to be the cause of a high percentage of cases of neonatal and chronic conjunctivitis in an inner-city population. To assess the etiology and epidemiology of acute conjunctivitis in this population, conjunctival scrapings were sampled from 45 patients presenting to an ocular emergency room; and replicate chlamydial, viral, and bacterial cultures and cytology tests were done. No cases of chlamydial conjunctivitis were diagnosed, although a viral etiology was established in 36% of the cases and a bacterial etiology in 40%. Twenty-four percent of the cases were not diagnosed. The authors recommend limiting the initial laboratory workup of patients with acute conjunctivitis to obtaining conjunctival smears for Gram and Giemsa staining. Chlamydial direct immunofluorescent monoclonal antibody (DFA) should be done if the patient is sexually active. Hyperacute conjunctivitis or acute conjunctivitis refractory to treatment mandates a more complete set of laboratory tests.

BACKGROUND:

Conjunctivitis is a relatively common condition of the eye that can be caused by a number of different pathogens including bacteria and viruses. Clinical differentiation between adenoviral and bacterial conjunctivitis is difficult, often resulting in misdiagnosis and the provision of inappropriate treatment.

METHODS:

A cost-effectiveness analysis was performed from a societal perspective using primary, secondary, published literature, and expert opinion data sources. The incremental costs and effects (cases of unnecessary antibiotic treatment avoided) for a rapid point-of-care test for adenoviral conjunctivitis (RPS Adeno Detector) were modeled.

RESULTS:

Using base case values, the incremental cost of using no point-of-care test compared with the point-of-care test is $71.30 with 0.1786 cases of unnecessary antibiotic treatment. Extrapolating these costs to the entire U.S. population per annum, society could potentially save nearly $430 million currently spent on unnecessary medical care and avoid over 1 million cases of unnecessary antibiotic treatment. The no-point-of-care test strategy is both more costly and less effective; indicating that the point-of-care test strategy is the most cost-effective option. The results were robust to variation in key model parameters.

CONCLUSIONS:

Through the use of a rapid point-of-care test for adenovirus, much of the cost to society caused by acute conjunctivitis can be avoided through more timely and accurate diagnosis.

Objetivo: Evaluar y comparar la eficacia y la tolerabilidad de uso tópico de fumarato de ketotifeno 0,05% de hidrocloruro de olopatadina 0,1% en el tratamiento de pacientes con conjuntivitis alérgica. Métodos: Se realizó enmascarado, estudio clínico aleatorizado que compara la eficacia , seguridad y efectos secundarios con el uso de la solución oftálmica de ketotifeno fumarato 0,05% de hidrocloruro de olopatadina 0,1% en el alivio de los signos y síntomas en pacientes con conjuntivitis alérgica. Treinta y cuatro pacientes que cumplan los criterios de inclusión del protocolo se les dio un frasco con la droga enmascarado, inculcar una gota dos veces al día en cada ojo durante 30 días. Los síntomas y signos de los pacientes fueron evaluados en una visita pre-tratamiento y cinco tratamiento (primero día, segundo día, 7 días, 14 días y 30 días). Resultados: La severidad de la conjuntivitis alérgica fue similar en ambos grupos de estudio. Tanto ketotifeno y olopatadina fueron equivalentes y eficaz en la disminución de los síntomas de picazón, ardor y lagrimeo. Los signos, hiperemia en conjuntiva bulbar fue atenuada en ambos grupos. Se observó Evaluación de las reacciones adversas en la quema de administración de ambos gotas para los ojos y la aparición de picor en el grupo de ketotifeno. No se observó ninguna reacción de hipersensibilidad a los fármacos estudiados. Conclusiones: Este estudio muestra que la solución oftálmica de ketotifeno fumarato 0,05% de hidrocloruro de olopatadina y 0,1% cuando se inculca dos veces al día durante 30 días, son eficaz y seguro en el alivio de los principales síntomas de la conjuntivitis alérgica.

We studied 102 children aged 1 month to 18 years in a randomized, double-blind trial designed to determine both the natural history of bacterial conjunctivitis and whether topical antibiotic therapy is beneficial. Affected eyes were treated four times a day for 7 days with drug (polymyxin-bacitracin ophthalmic ointment) or placebo. Eighty-four patients had proved bacterial conjunctivitis (Haemophilus influenzae 61, Streptococcus pneumoniae 22, both one); 66 of these received only topical therapy. By 3 to 5 days, 21 of 34 (62%) patients receiving topical antibiotic were clinically cured, whereas only nine of 32 (28%) patients given placebo were cured (P less than 0.02). By 8 to 10 days, 31 (91%) of the patients given antibiotic and 23 (72%) of the placebo group were cured (P = NS). The bacterial pathogen was eradicated by day 3 to 5 in 71% and by day 8 to 10 in 79% of patients given antibiotic, compared to 19% and 31% of the placebo group (P less than 0.001). Acute bacterial conjunctivitis is a self-limited disease, but topical antibiotic therapy with polymyxin-bacitracin shortens the duration of clinical disease and enhances eradication of the causative organism from the conjunctiva.

Azelastine (CAS 58581-89-8) is a selective H1-receptor antagonist that inhibits histamine release and interferes with activation of other mediators of allergic inflammation. The present double-blind study aimed to evaluate azelastine eye drops (Allergodil) in patients with perennial allergic conjunctivitis compared to placebo. A total of 116 patients with an ocular symptoms score for itching and conjunctival redness > or = 3 (0-6 scale) were randomized to twice-daily 0.05% azelastine eye drops treatment (n = 58) or placebo. Patients maintained daily logs and were clinically evaluated after 7, 21 and 42 days of treatment. Azelastine significantly improved itching and conjunctival redness versus placebo (p < 0.001). Tolerability was rated good or better by 97% of patients with only bitter taste and application site reaction notable adverse experiences. On Day 7, ocular symptoms score improved by 1.5 +/- 0.9 (versus 0.5 +/- 0.8 placebo) with score improvement > or = 2 in 55% with azelastine (versus 14% placebo). Itching and redness further improved at Day 42 (score improvement > or = 2 in 95% with azelastine versus 33% placebo) and completely resolved for 47% azelastine patients (versus 10% placebo). Daily patient logs confirmed the clinically assessed scores. Topical azelastine progressively improved itching and conjunctival redness in patients with moderate to severe perennial allergic conjunctivitis. Continued improvement with prolonged use is consistent with mechanisms other than H1-receptor blockade, such as possible down regulation of adhesion molecule receptors.

One hundred fifty-eight patients, 21 years of age or less, presenting with culture-positive (Haemophilus influenzae or Streptococcus pneumoniae) conjunctivitis were treated with trimethoprim-polymyxin B (TP), gentamicin sulfate (GS) or sodium sulfacetamide (SS) ophthalmic solution for 10 days. Clinical response at 3 to 6 days after start of therapy was similar for all test agents: 26 of 55 (47%) patients cured, 25 of 55 (45%) improved for TP; 28 of 57 (49%) cured, 26 of 57 (46%) improved for GS; and 19 of 46 (41%) cured, 22 of 46 (48%) improved for SS. Clinical response at 2 to 7 days after completion of therapy was also similar: 46 of 55 (84%) patients cured, 5 of 55 (9%) improved for TP; 50 of 57 (88%) cured, 5 of 57 (9%) improved for GS; and 41 of 46 (89%) cured, 2 of 46 (4%) improved for SS. Bacteriologic response at 2 to 7 days after completion of therapy was similar for all antimicrobials: 44 of 55 (83%) patients for TP; 39 of 57 (68%) for GS; and 33 of 46 (72%) for SS.